Patents by Inventor James Dennen O'Neil
James Dennen O'Neil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9115072Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I or a pharmaceutically acceptable salt thereof. In Formula I m is 0, 1, 2, 3 or 4; n is 0 or 1; m+n is not more than 4; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R6 is hydrogen, methyl or ethyl and R12 is hydrogen or methyl, or R6 is hydroxy and R12 is hydrogen, or R6 is O and R12 is absent, or R6 and R12 together are —CH2CH2—. R7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R8 and R9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R11) wherein R11 is hydrogen or alkyl having from 1 to 3 carbon atoms.Type: GrantFiled: May 9, 2013Date of Patent: August 25, 2015Assignee: Wellstat Therapeutics CorporationInventors: James Dennen O'Neil, Michael K Bamat, Reid W von Borstel, Shalini Sharma, Ramachandran Arudchandran
-
Patent number: 8889724Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and Plasmodium falciparum-induced inflammation.Type: GrantFiled: March 4, 2013Date of Patent: November 18, 2014Assignee: Wellstat Therapeutics CorporationInventors: James Dennen O'Neil, Shalini Sharma, Ramachandran Arudchandran
-
Patent number: 8829058Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I or a pharmaceutically acceptable salt thereof. In Formula I m is 0, 1, 2, 3 or 4; n is 0 or 1; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R6 is hydrogen, O or hydroxyl. R7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R8 and R9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R11) wherein R11 is hydrogen or alkyl having from 1 to 3 carbon atoms.Type: GrantFiled: March 13, 2009Date of Patent: September 9, 2014Assignee: Wellstat Therapeutics CorporationInventors: James Dennen O'Neil, Michael K. Bamat, Reid W. von Borstel, Shalini Sharma, Ramachandran Arudchandran
-
Publication number: 20130336949Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and Plasmodium falciparum-induced inflammation.Type: ApplicationFiled: March 4, 2013Publication date: December 19, 2013Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: James Dennen O'Neil, Shalini Sharma, Ramachandran Arudchandran
-
Publication number: 20130259850Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I or a pharmaceutically acceptable salt thereof. In Formula I m is 0, 1, 2, 3 or 4; n is 0 or 1; m+n is not more than 4; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R6 is hydrogen, methyl or ethyl and R12 is hydrogen or methyl, or R6 is hydroxy and R12 is hydrogen, or R6 is O and R12 is absent, or R6 and R12 together are —CH2CH2—. R7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R8 and R9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R11) wherein R11 is hydrogen or alkyl having from 1 to 3 carbon atoms.Type: ApplicationFiled: May 9, 2013Publication date: October 3, 2013Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: James Dennen O'NEIL, Michael K. BAMAT, Reid W. von BORSTEL, Shalini SHARMA, Ramachandran ARUDCHANDRAN
-
Patent number: 8410154Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and Plasmodium falciparum-induced inflammation. In Formula 1, x is 1 or 2: y is O, 1, 2 or 3; and R1 is selected from the group consisting of hydrogen, alkyl having 1 or 2 carbon atoms, hydroxy, alkoxy having 1 or 2 carbon atoms, fluoro, chloro, bromo, and amino.Type: GrantFiled: April 30, 2009Date of Patent: April 2, 2013Assignee: Wellstat Therapeutics CorporationInventors: James Dennen O'Neil, Shalini Sharma, Ramachandran Arudchandran
-
Publication number: 20120201803Abstract: A process for forming a solid electrolytic capacitor and an electrolytic capacitor formed by the process. The process includes: providing an anode wherein the anode comprises a porous body and an anode wire extending from the porous body; applying a thin polymer layer onto the dielectric, and forming a dielectric on the porous body to form an anodized anode; applying a first slurry to the anodized anode to form a blocking layer wherein the first slurry comprises a first conducting polymer with an median particle size of at least 0.05 ?m forming a layer of crosslinker on the blocking layer; and applying a layer of a second conducting polymer on the layer of crosslinker.Type: ApplicationFiled: September 15, 2011Publication date: August 9, 2012Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: Shalini Sharma, James Dennen O'Neil, Reid W. von Borstel, Ramchandran Arudchandran
-
Publication number: 20120078529Abstract: A severity score for 5-fluorouracil (5FU) toxicity is calculated by taking the square root of the sum of: (a) the square of the logarithm of the dose of 5-fluorouracil administered to the patient; and (b) the square of the logarithm of the administration rate of the 5-fluorouracil to the patient. Severity Score=[(log Dose)2+(log Rate)2]1/2.Type: ApplicationFiled: May 11, 2010Publication date: March 29, 2012Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: James Dennen O'Neil, Reid W. von Borstel
-
Publication number: 20110206653Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and Plasmodium falciparum-induced inflammation. In Formula 1, x is 1 or 2: y is O, 1, 2 or 3; and R1 is selected from the group consisting of hydrogen, alkyl having 1 or 2 carbon atoms, hydroxy, alkoxy having 1 or 2 carbon atoms, fluoro, chloro, bromo, and amino.Type: ApplicationFiled: April 30, 2009Publication date: August 25, 2011Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: James Dennen O'Neil, Shalini Sharma, Ramachandran Arudchandran
-
Publication number: 20110014176Abstract: This invention pertains to the discovery that certain extracts of licorice, particularly when formulated as a candy or lollipop or other means that provides an extended release (e.g., greater than about 4 minutes) to the oral cavity significantly inhibits the formation of dental caries in a human subject.Type: ApplicationFiled: March 13, 2009Publication date: January 20, 2011Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: James Dennen O'Neil, Michael K. Bamat, Reid W. von Borstel, Shalini Sharma, Ramachandran Arudchandran